147 related articles for article (PubMed ID: 2151629)
1. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
Mallmann P; Dietrich K; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
[TBL] [Abstract][Full Text] [Related]
2. [Effect of tamoxifen on parameters of cell-mediated immunity in postmenopausal patients with breast carcinoma].
Mallmann P; Krebs D
Zentralbl Gynakol; 1991; 113(12):689-96. PubMed ID: 1927118
[TBL] [Abstract][Full Text] [Related]
3. Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin.
Mallmann P; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Jun; 12(5):333-40. PubMed ID: 2232966
[TBL] [Abstract][Full Text] [Related]
4. Determination of TNF alpha, interferon alpha, interleukin 2 and reactivity in the leucocyte migration inhibition test in breast cancer patients.
Mallmann P; Diedrich K; Mallmann R; Koenig UD; Krebs D
Anticancer Res; 1991; 11(4):1509-15. PubMed ID: 1746907
[TBL] [Abstract][Full Text] [Related]
5. [The effect of adjuvant combined chemo/immunotherapy on immunological parameters and clinical course in patients with breast carcinoma].
Mallmann P; Krebs D
Zentralbl Gynakol; 1991; 113(12):697-706. PubMed ID: 1927119
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines.
Sica G; Iacopino F; Marini L; Robustelli della Cuna G
Clin Ther; 1992; 14 Suppl A():87-96. PubMed ID: 1535023
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
[TBL] [Abstract][Full Text] [Related]
8. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M
Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004
[TBL] [Abstract][Full Text] [Related]
9. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863).
Beex L; Rose C; Mouridsen H; Jassem J; Nooij M; Estape J; Paridaens R; Piccart M; Gorlia T; Lardenoije S; Baila L
Eur J Cancer; 2006 Dec; 42(18):3178-85. PubMed ID: 17045796
[TBL] [Abstract][Full Text] [Related]
10. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
[TBL] [Abstract][Full Text] [Related]
11. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
12. [Experimental study of combination medical endocrine therapy on DMBA-induced mammary tumor, with special reference to the effect of drug-dose on various factors].
Kosaka A; Yamashita A
Gan To Kagaku Ryoho; 1992 Jan; 19(1):75-81. PubMed ID: 1530907
[TBL] [Abstract][Full Text] [Related]
13. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
14. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
[TBL] [Abstract][Full Text] [Related]
15. [A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate].
Tsumura I; Okamura Y; Takatsuka Y; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1509-12. PubMed ID: 2143889
[TBL] [Abstract][Full Text] [Related]
16. [Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer].
Mitsuyama S; Kuroda Y; Ohsato K; Nakamura Y; Murakami F; Nishikata F; Ikeda S; Egami T; Mori A; Ohe H
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1153-60. PubMed ID: 8751803
[TBL] [Abstract][Full Text] [Related]
17. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
Noguchi S; Yamamoto H; Inaii H; Koyama H
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
[TBL] [Abstract][Full Text] [Related]
18. Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma.
Yamashita J; Hideshima T; Shirakusa T; Ogawa M
Cancer; 1996 Dec; 78(11):2346-52. PubMed ID: 8941005
[TBL] [Abstract][Full Text] [Related]
19. [Does interferon-alpha enhance the effect of tamoxifen-medroxyprogesterone acetate and hydroxyflutamide on in vitro tumor cells?].
Werner A; Aichberger A; Krebs D
Zentralbl Gynakol; 1996; 118(11):616-21. PubMed ID: 9082695
[TBL] [Abstract][Full Text] [Related]
20. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
